Although several potential biomarkers (such as PD-L1, dMMR, and tumor mutational burden) were demonstrated for gastric cancer patients to predict the superior efficacy of immunotherapy, peritoneal metastases show PD-L1 expression less frequently (44). Here, CD274 is linked to gastric cancer.